Aurinia Pharmaceuticals Return on Equity

Aurinia Pharmaceuticals (AUPH) currently reports a ROE of 51.09%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Aurinia Pharmaceuticals's ROE history and peer comparisons.

Aurinia Pharmaceuticals's ROE of 51.09% is higher than the Healthcare sector average of 22.01%. That is roughly 132.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aurinia Pharmaceuticals's current 51.09% should be judged against Healthcare norms (sector average: 22.01%) and against AUPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 51.09%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Aurinia Pharmaceuticals, and consider following AUPH for alerts when major investors trade the stock.

Aurinia Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 51.09% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AUPH with unrelated industries.